サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1529863

ホルモン剤避妊の市場規模、シェア、動向分析レポート：方法別、ホルモン別、地域別、セグメント予測、2024年～2030年

Hormonal Contraceptive Market Size, Share & Trends Analysis Report By Method (Pill, IUD), By Hormone (Combination Hormonal Contraceptives, Progestin-only), By Region (North America, Europe), And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
ホルモン剤避妊の市場規模、シェア、動向分析レポート：方法別、ホルモン別、地域別、セグメント予測、2024年～2030年
出版日: 2024年07月26日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ホルモン剤避妊市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のホルモン剤避妊の市場規模は2030年までに212億1,000万米ドルに達し、2024年から2030年までのCAGRは4.01％で成長すると予測されています。

同市場の成長は、革新的な製品のイントロダクションと新興地域におけるリプロダクティブヘルスに対する意識の高まりによって牽引されると予想されます。新興経済諸国では、政府の取り組みやプログラムの増加により避妊具を使用する女性が増えており、これが市場成長を加速すると予想されます。例えば、国連のWorld Fertility and Family Planning 2022によると、2021年には生殖年齢にある19億人の女性が妊娠を避けるために何らかの避妊を受けており、そのうち77％の女性がインプラント、パッチ、IUDなどを含む最新の避妊法を使用しています。

国連人口基金（UNFPO）の『世界人口の現状2022』によると、世界全体では、毎年1億2,100万件の妊娠のうち約50％が望まない妊娠です。Seeing the Unseen（見えないものを見る）』報告書の通りである：The case for action in the neglected crisis of unintended pregnancy "によれば、望まない妊娠の60％以上が中絶に至り、そのうち45％は安全でない妊娠であると予測されています。それゆえ、安全でない中絶を避けるために、各国は避妊薬に関する認識を広めており、これが業界の成長を促進すると予想されます。

市場競争が激しいため、企業は研究開発に多額の投資を行っています。また、M&Aや製品パイプラインの拡充など、さまざまな戦略を採用しています。例えば、オルガノン・グループ・オブ・カンパニーズは2022年2月、マカオと香港を含む中華人民共和国において、バイエルAGから経口ホルモン剤配合の日用避妊薬「マーシロン」と「マーベロン」の権利を取得しました。さらに、これらの製品に関するベトナムでの権利取得にも合意しました。今回の買収は、韓国を除く全世界におけるこれらのブランドの所有権を得ることを目的としています。

ホルモン剤避妊市場レポートハイライト

  • 方法別では、ピルが2023年に市場を席巻しました。これは、効率的で簡単な投与法、容易に入手可能な製品、長時間作用型可逆的デバイスと比較した早期イントロダクションよる市場認知度の向上、適切な使用による約99%の有効性、多くのプレーヤーの存在が同分野の成長に寄与しているためです。
  • ホルモン別では、ホルモン併用避妊薬セグメントは、副作用が少なく、にきびや関連症状を発症する可能性が低いことから、2023年の市場を独占しました。
  • 北米地域が2023年に最大の市場シェアを占めました。これは、大手企業が存在すること、望まない妊娠の割合が高いこと、一人当たりの所得が高いこと、政府の取り組みが支持的であることなどに起因します。
  • 2023年6月、製薬会社のGedeon Richter UK Limitedは、Consilient Health Ltd.から避妊薬ブランドジェネリックの全販売・販売権を3,517万米ドル（3,250万ユーロ）で取得しました。この買収は、英国全土でこの製品を手頃な価格で提供することを目的としています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • ポーターのファイブフォース分析
    • PESTLE分析

第4章 ビジネス分析：方法別

  • 方法別市場シェア、2023年と2030年
  • 方法別セグメントダッシュボード
  • 市場規模と予測および動向分析、方法別、2018～2030年
  • ピル
    • ピル市場推計・予測、2018年-2030年
  • IUD
    • IUD市場推計・予測、2018年-2030年
  • 注射
    • 注射剤市場推計・予測、2018年-2030年
  • 膣リング
    • 膣リング市場推計・予測、2018年-2030年
  • インプラント
    • インプラント市場推計・予測、2018年-2030年
  • パッチ
    • パッチ市場推計・予測、2018年-2030年

第5章 ビジネス分析：ホルモン別

  • ホルモン別市場シェア、2023年と2030年
  • ホルモン別セグメントダッシュボード
  • ホルモン別の市場規模と予測および動向分析、2018～2030年
  • 複合ホルモン剤避妊
    • 複合ホルモン剤避妊市場推計・予測、2018年-2030年
  • プロゲスチンのみ
    • プロゲスチンのみの市場推計・予測、2018年-2030年

第6章 方法とタイプ別の地域推定・動向分析

  • 地域別市場シェア分析、2023年および2030年
  • 地域別市場ダッシュボード
  • 市場規模と予測動向分析、2018年から2030年
  • 北米
    • 北米のホルモン剤避妊市場推計・予測、2018年-2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州のホルモン剤避妊市場推計・予測、2018年-2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • アジア太平洋地域のホルモン剤避妊市場推計・予測、2018年-2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカのホルモン剤避妊市場推計・予測、2018年-2030年
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカホルモン剤避妊市場推計・予測、2018-2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参入企業概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/リスト
    • AbbVie Inc.
    • Bayer AG
    • Organon group of companies.
    • Pfizer Inc.
    • Afaxys, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Agile Therapeutics
    • Johnson &Johnson Services, Inc.
    • Lupin Pharmaceuticals, Inc.
    • Pregna International Limited.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 4 Global hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 5 Global hormonal contraceptive market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America hormonal contraceptive market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 8 North America hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 9 U.S hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 10 U.S hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 11 Canada hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 12 Canada hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 13 Mexico hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 14 Mexico hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 15 Europe hormonal contraceptive market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 17 Europe hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 18 UK hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 19 UK hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 20 Germany hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 21 Germany hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 22 France hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 23 France hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 24 Italy hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 25 Italy hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 26 Spain hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 27 Spain hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 28 Norway hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 29 Norway hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 30 Sweden hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 31 Sweden hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 32 Denmark hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 33 Denmark hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific hormonal contraceptive market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 37 Japan hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 38 Japan hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 39 China hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 40 China hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 41 India hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 42 India hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 43 Australia hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 44 Australia hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 45 South Korea hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 46 South Korea hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 47 Thailand hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 48 Thailand hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 49 Latin America hormonal contraceptive market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 51 Latin America hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 52 Brazil hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 53 Brazil hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 54 Argentina hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 55 Argentina hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa hormonal contraceptive market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 59 South Africa hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 60 South Africa hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 63 UAE hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 64 UAE hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)
  • Table 65 Kuwait hormonal contraceptive market, by method, 2018 - 2030 (USD Million)
  • Table 66 Kuwait hormonal contraceptive market, by hormone, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market segmentation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Market trends & outlook
  • Fig. 12 Market driver relevance analysis (current & future impact)
  • Fig. 13 Market restraint relevance analysis (current & future impact)
  • Fig. 14 PESTLE analysis
  • Fig. 15 Porter's Five Forces analysis
  • Fig. 16 Hormonal contraceptive market: Method outlook and key takeaways
  • Fig. 17 Hormonal contraceptive market: Method movement analysis
  • Fig. 18 Pill market revenue, 2018 - 2030 (USD Million)
  • Fig. 19 IUD market revenue, 2018 - 2030 (USD Million)
  • Fig. 20 Injectable market revenue, 2018 - 2030 (USD Million)
  • Fig. 21 Vaginal ring market revenue, 2018 - 2030 (USD Million)
  • Fig. 22 Implant market revenue, 2018 - 2030 (USD Million)
  • Fig. 23 Patch market revenue, 2018 - 2030 (USD Million)
  • Fig. 24 Hormonal contraceptive market: Hormone outlook and key takeaways
  • Fig. 25 Hormonal contraceptive market: Hormone movement analysis
  • Fig. 26 Combined hormone contraceptive market revenue, 2018 - 2030 (USD Million)
  • Fig. 27 Progestin only market revenue, 2018 - 2030 (USD Million)
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 Regional outlook, 2023 & 2030
  • Fig. 30 Hormonal contraceptive market: Region movement analysis
  • Fig. 31 North America hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 32 US hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 33 Key country dynamics
  • Fig. 34 Canada hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 35 Key country dynamics
  • Fig. 36 Mexico hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 Europe hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 39 Germany hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 UK hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 France hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Italy hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Spain hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Sweden hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Norway hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Denmark hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Asia Pacific hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 China hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 India hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Australia hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 South Korea hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Thailand hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Latin America hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 69 Brazil hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Argentina hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Middle East and Africa hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Saudi Arabia hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 UAE hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Kuwait hormonal contraceptive market, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Company categorization
  • Fig. 83 Strategy mapping
  • Fig. 84 Company market position analysis
目次
Product Code: GVR-2-68038-348-5

Hormonal Contraceptive Market Growth & Trends:

The global hormonal contraceptive market size is anticipated to reach USD 21.21 billion by 2030, growing at a CAGR of 4.01% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is expected to be driven by the introduction of innovative products and increasing awareness about reproductive health in emerging regions. More women in developing economies are using contraceptives due to the rise in government initiatives and programs, which is anticipated to accelerate market growth. For instance, according to the UN World Fertility and Family Planning 2022, in 2021, 1.9 billion women of reproductive age received some form of contraception to avoid pregnancy with 77% of women among them using modern contraceptive methods including implants, patches, IUDs, and others.

According to the State of World Population 2022, by UNFPO, globally, approximately 50% of all 121 million pregnancies each year are unwanted. As per the Seeing the Unseen report: The case for action in the neglected crisis of unintended pregnancy, more than 60% of unwanted pregnancies result in abortion and the projected 45% among them are unsafe. Hence, to avoid unsafe abortions, countries are spreading awareness about contraceptives, which is expected to propel industry growth.

Due to the highly competitive nature of the market, companies are making significant investments in research and development. They are also adopting various strategies such as mergers and acquisitions and expanding their product pipelines. For instance, in February 2022, Organon Group of Companies acquired rights of Mercilon and Marvelon, combined oral hormonal daily contraceptive pills from Bayer AG in the People's Republic of China, including Macau and Hong Kong. In addition, it has agreed to acquire rights in Vietnam to these products. This acquisition aims to provide global ownership rights of these brands, except in South Korea.

Hormonal Contraceptive Market Report Highlights:

  • Based on method, the pill segment dominated the market in 2023 owing to the efficient and straightforward administration, readily accessible products, enhanced market awareness due to early introduction compared to long-acting reversible devices, and an approximate 99% effectiveness with proper usage, and the presence of many players contribute to the segment growth.
  • Based on hormone, the combination hormonal contraceptive segment dominated the market in 2023 owing to the fewer side effects and lower chances of developing acne and related symptoms.
  • North America region held the largest market share in 2023. This can be attributed to the existence of major players, a high proportion of unwanted pregnancies, high per capita income, and supportive government initiatives.
  • In June 2023, Gedeon Richter UK Limited, a pharmaceutical company, acquired full distribution and marketing rights of a contraceptive range of branded generics from Consilient Health Ltd. for USD 35.17 million (Euro 32.5 million). This acquisition aims to provide this product at affordable prices across the UK.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Method
    • 1.2.2. Hormone
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
    • 1.8.2. Volume Price Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rise in government and NGO initiatives to promote contraceptive methods
      • 3.2.1.2. High unmet needs
      • 3.2.1.3. Increasing R&D investments
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Rapidly aging population and rising prevalence of infertility
      • 3.2.2.2. Adverse effects associated with the use of contraceptive drugs and devices
  • 3.3. Business Environment Analysis
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Method Business Analysis

  • 4.1. Method Market Share, 2023 & 2030
  • 4.2. Method Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Method, 2018 to 2030 (USD Million)
  • 4.4. Pill
    • 4.4.1. Pill market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. IUD
    • 4.5.1. IUD market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Injectable
    • 4.6.1. Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.7. Vaginal Ring
    • 4.7.1. Vaginal ring market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.8. Implant
    • 4.8.1. Implant market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.9. Patch
    • 4.9.1. Patch market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hormone Business Analysis

  • 5.1. Hormone Market Share, 2023 & 2030
  • 5.2. Hormone Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analyses, by Hormone, 2018 to 2030 (USD Million)
  • 5.4. Combination Hormonal Contraceptives
    • 5.4.1. Combination hormonal contraceptives market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Progestin Only
    • 5.5.1. Progestin only market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Regional Estimates & Trend Analysis by Method & Type

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key country dynamic
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. U.S. hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key country dynamic
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. Canada hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key country dynamic
      • 6.4.4.2. Regulatory framework
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Mexico hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key country dynamic
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Germany hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. UK
      • 6.5.3.1. Key country dynamic
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. UK hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key country dynamic
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. France hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key country dynamic
      • 6.5.5.2. Regulatory framework
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Italy hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key country dynamic
      • 6.5.6.2. Regulatory framework
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Spain hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key country dynamic
      • 6.5.7.2. Regulatory framework
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. Denmark hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key country dynamic
      • 6.5.8.2. Regulatory framework
      • 6.5.8.3. Competitive scenario
      • 6.5.8.4. Sweden hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key country dynamic
      • 6.5.9.2. Regulatory framework
      • 6.5.9.3. Competitive scenario
      • 6.5.9.4. Norway hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key country dynamic
      • 6.6.2.2. Regulatory framework
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Japan hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key country dynamic
      • 6.6.3.2. Regulatory framework
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. China hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key country dynamic
      • 6.6.4.2. Regulatory framework
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. India hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key country dynamic
      • 6.6.5.2. Regulatory framework
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. South Korea hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key country dynamic
      • 6.6.6.2. Regulatory framework
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Australia hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key country dynamic
      • 6.6.7.2. Regulatory framework
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Thailand hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key country dynamic
      • 6.7.2.2. Regulatory framework
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Brazil hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key country dynamic
      • 6.7.3.2. Regulatory framework
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. Argentina hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key country dynamic
      • 6.8.2.2. Regulatory framework
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. South Africa hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key country dynamic
      • 6.8.3.2. Regulatory framework
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Saudi Arabia hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key country dynamic
      • 6.8.4.2. Regulatory framework
      • 6.8.4.3. Competitive scenario
      • 6.8.4.4. UAE hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key country dynamic
      • 6.8.5.2. Regulatory framework
      • 6.8.5.3. Competitive scenario
      • 6.8.5.4. Kuwait hormonal contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbVie Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial performance
      • 7.5.1.3. Product benchmarking
      • 7.5.1.4. Strategic initiatives
    • 7.5.2. Bayer AG
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial performance
      • 7.5.2.3. Product benchmarking
      • 7.5.2.4. Strategic initiatives
    • 7.5.3. Organon group of companies.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial performance
      • 7.5.3.3. Product benchmarking
      • 7.5.3.4. Strategic initiatives
    • 7.5.4. Pfizer Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial performance
      • 7.5.4.3. Product benchmarking
      • 7.5.4.4. Strategic initiatives
    • 7.5.5. Afaxys, Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial performance
      • 7.5.5.3. Product benchmarking
      • 7.5.5.4. Strategic initiatives
    • 7.5.6. Teva Pharmaceutical Industries Ltd.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial performance
      • 7.5.6.3. Product benchmarking
      • 7.5.6.4. Strategic initiatives
    • 7.5.7. Agile Therapeutics
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial performance
      • 7.5.7.3. Product benchmarking
      • 7.5.7.4. Strategic initiatives
    • 7.5.8. Johnson & Johnson Services, Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial performance
      • 7.5.8.3. Product benchmarking
      • 7.5.8.4. Strategic initiatives
    • 7.5.9. Lupin Pharmaceuticals, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial performance
      • 7.5.9.3. Product benchmarking
      • 7.5.9.4. Strategic initiatives
    • 7.5.10. Pregna International Limited.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial performance
      • 7.5.10.3. Product benchmarking
      • 7.5.10.4. Strategic initiatives